Shares of Dynavax Technologies Corporation (NASDAQ: DVAX) Climb on Successful Phase 3 Trial and Second Quarter Financial Results
Dynavax Technologies Corporation (NASDAQ: DVAX), a developer of innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergy, cancer and chronic inflammatory diseases by utilizing versatile, proprietary approaches to alter immune system responses, recently announced the results form a Phase 3 clinical trial and the company’s second quarter financial results. Shares of Dynavax Technologies climbed higher earlier this week after the company announced positive top line results from a Phase 3 clinical trial comparing HEPLISAV™, an investigational hepatitis B virus vaccine, to a currently marketed HBV vaccine, GlaxoSmith Kline’s Engerix-B®. This clinical trial showed that 95.1 percent of subjects…